Marcos Letaif Gaeta

Marcos Letaif Gaeta

Auto-generated profile, based on publicly available information

Marcos Letaif Gaeta

Laboratory of Fish Bacteriology, Department of Preventive Veterinary Medicine, State University of Londrina, Londrina 86057-970, Paraná, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2024 in Fishes
Verified
Journal Article
Open access
PDF file
NFNatália Amoroso Ferrari
Natália Amoroso Ferrari
LFLeonardo Mantovani Favero
Leonardo Mantovani Favero
CFCesar Toshio Facimoto
Cesar Toshio Facimoto
AAAlais Maria Dall Agnol
Alais Maria Dall Agnol
MGMarcos Letaif Gaeta
Marcos Letaif Gaeta
GSGiovana Wingeter Di Santis
Giovana Wingeter Di Santis
Streptococcus agalactiae is a highly invasive bacterium that causes significant economic losses in tilapia aquaculture around the world. Furthermore, it is a pathogen for mammals, including humans, emphasizing its importance in One Health. The aim of this work was to evaluate the evolution of clinical and histopathological lesions caused by acute infection with two serotypes of S. agalactiae. For this, two strains isolated from natural outbreaks in Brazilian aquaculture farms (S13, serotype Ib; S73, serotype III) were used to challenge juvenile Nile tilapia (Oreochromis niloticus) intraperitoneally. Target organ samples were collected ten times, between 1 and 96 h post-infection, for microbiological and histopathological analyses. Anorexia was the first clinical sign and the first death occurred at 24 and 30 h in the fish infected with strains S13 and S73, respectively. Serotype Ib initially caused more pronounced lesions in the nervous system; however, serotype III lesions progressed more aggressively, reaching the same severity as those of serotype Ib. This trend was repeated in the mortality curve after 32 h. These results elucidated the important stages in the pathogenesis of S. agalactiae serotypes Ib and III in tilapia and suggest “tips and tricks” to improve the positive culture rate in the clinical diagnosis of infections in some tissues.

1 March 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
NFNatália Amoroso Ferrari
Natália Amoroso Ferrari
RMRaffaella Menegheti Mainardi
Raffaella Menegheti Mainardi
MSMayza Brandão da Silva
Mayza Brandão da Silva
GGGabriel Diogo Guimarães
Gabriel Diogo Guimarães
MGMarcos Letaif Gaeta
Marcos Letaif Gaeta
Ulisses de De Pádua PereiraUlisses de De Pádua Pereira
Ulisses de De Pádua Pereira
This study evaluates the efficacy of a new florfenicol-based drug, both in vitro and in vivo, in Nile tilapia (Oreochromis niloticus) against pathogens commonly found in fish farming and its withdrawal period. The drug’s efficacy was tested using prophylactic, metaphylactic, and therapeutic approaches against Streptococcus agalactiae (serotypes Ib and III) and Francisella orientalis. The minimum inhibitory concentration of florfenicol was 4, 5, and 128 μg/mL for the different pathogens. Fish mortality was lower in the prophylactic treatment compared to the metaphylactic and therapeutic treatments for S. agalactiae. No difference in mortality was observed for F. orientalis across treatments. Mild to moderate lesions suggestive of intoxication were observed, mainly in the liver of fish treated with overdoses or exposed to low temperatures. Florfenicol reduced mortality rates, especially with early treatment (metaphylactic), in fish experimentally challenged with the pathogens. Moreover, prophylactic antimicrobial use is not recommended, as it promotes the selection of multidrug-resistant bacterial strains. Additionally, the residual concentration of the drug in muscle tissue lasted for a shorter period than that recommended by the manufacturer, and at lower concentrations than required by national and international legislation.